MedTech Dive May 17, 2024
Burke Barrett will take over the role effectively immediately, while former CEO Kevin Danahy will become the chief commercial officer.
Name: Burke Barrett
New title: CEO, Pulse Biosciences
Previous title: CEO, Cardiofocus
Pulse Biosciences has appointed Burke Barrett as CEO. The appointment sees the former CEO Kevin Danahy become chief commercial officer to focus on the launch of a pulsed field ablation (PFA) device.
California-based Pulse has developed technology that delivers nanosecond-duration pulses of electrical energy. Applied to atrial fibrillation (AFib), Pulse says the technology can improve on existing surgical thermal technologies by delivering faster ablations through thicker tissue. The company also sees potential safety advantages.
Pulse received 510(k) clearance for its Cellfx electrode system in March. The clearance is...
Today's Sponsors
Today's Sponsor